AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17201838 — intervention group
Group type: EXPERIMENTAL
Intervention: para-Hisian pacing (PHP)
Number of subjects: 17
Study 12747273 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac hydroxyethylpyrrolidine (DHEP) patch
Number of subjects: 103
Study 12747273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 10905443 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted screw application using an optoelectronic navigation system
Number of subjects: 100
Study 10905443 — intervention group
Group type: COMPARATOR
Intervention: Conventional pedicle screw placement
Number of subjects: 100
Study 8853276 — intervention group
Group type: EXPERIMENTAL
Intervention: T20 (20 degrees C and 20% RH)
Number of subjects: 7
Study 8853276 — intervention group
Group type: COMPARATOR
Intervention: T3 (3 degrees C and approximately 50% RH)
Number of subjects: 7
Study 1320133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol 9 sponge
Number of subjects: 138
Study 1320133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 6389648 — intervention group
Group type: EXPERIMENTAL
Intervention: aqueous mixed-grass extract
Number of subjects: 45
Study 6389648 — intervention group
Group type: COMPARATOR
Intervention: allergoid mixed-grass extract
Number of subjects: 45
Study 6389648 — intervention group
Group type: COMPARATOR
Intervention: histamine placebo
Number of subjects: 45
Study 6389648 — intervention group
Group type: COMPARATOR
Intervention: aqueous mixed-grass extract, allergoid, histamine placebo
Number of subjects: 45
Study 6389648 — intervention group
Group type: COMPARATOR
Intervention: allergoid grass extract
Number of subjects: 45
Study 6389648 — intervention group
Group type: EXPERIMENTAL
Intervention: LNIT
Number of subjects: 45
Study 31010102 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Mom Zone intervention
Number of subjects: 27
Study 31010102 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 29544162 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant zoledronic acid (ZOL) 4 mg administered by intravenous infusion every 3-4 weeks for 6 doses, then 3 monthly × 8 and 6 monthly × 5 for 5 years.
Number of subjects: 244
Study 29544162 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant zoledronic acid (ZOL)
Number of subjects: 244
Study 29544162 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard therapy)
Number of subjects: 244
Study 26677940 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb
Number of subjects: 253
Study 26677940 — intervention group
Group type: COMPARATOR
Intervention: QFT-GIT
Number of subjects: 253
Study 26677940 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb in HIV-infected patients
Number of subjects: 253
Study 26677940 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb in HIV-uninfected patients
Number of subjects: 253
Study 26677940 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb and QFT-GIT combined
Number of subjects: 253
Study 25069559 — intervention group
Group type: EXPERIMENTAL
Intervention: Questioning-training by providing prompts (G1)
Number of subjects: 72
Study 25069559 — intervention group
Group type: EXPERIMENTAL
Intervention: Question-generation without any explicit instruction (G2)
Number of subjects: 72
Study 25069559 — intervention group
Group type: COMPARATOR
Intervention: No question control (G3)
Number of subjects: 72
Study 22174346 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-dexmedetomidine (Group PD)
Number of subjects: 72
Study 22174346 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil (Group PR)
Number of subjects: 72
Study 20814780 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited portal carpal tunnel release
Number of subjects: 161
Study 20814780 — intervention group
Group type: COMPARATOR
Intervention: Classic open release
Number of subjects: 161
Study 18609474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC) dosed twice daily
Number of subjects: 31
Study 18609474 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost dosed every evening
Number of subjects: 31
Study 18609474 — intervention group
Group type: COMPARATOR
Intervention: Timolol run-in
Number of subjects: 31
Study 16268183 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast plus beclomethasone
Number of subjects: 30
Study 16268183 — intervention group
Group type: COMPARATOR
Intervention: Surgery-montelukast-beclomethasone
Number of subjects: 30
Study 16268183 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Group 2)
Number of subjects: 30
Study 12045163 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein (CRP) levels
Number of subjects: 97
Study 12045163 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels (highest quartile)
Number of subjects: 97
Study 12045163 — intervention group
Group type: COMPARATOR
Intervention: Homocysteine and lipid levels
Number of subjects: 97
Study 9887649 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videotape
Number of subjects: 62
Study 9887649 — intervention group
Group type: COMPARATOR
Intervention: Routine educational care (Control)
Number of subjects: 62
Study 7872219 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (400 mL/d for 2 weeks)
Number of subjects: 17
Study 7872219 — intervention group
Group type: COMPARATOR
Intervention: White wine (400 mL/d for 2 weeks)
Number of subjects: 17
Study 2205329 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 101
Study 2205329 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 101
Study 629844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (20 mg/kg/day for 3 days)
Number of subjects: 48
Study 629844 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole
Number of subjects: 48
Study 629844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 48
Study 629844 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 30056562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Number of subjects: 191
Study 30056562 — intervention group
Group type: COMPARATOR
Intervention: Oral Iron
Number of subjects: 191
Study 30056562 — intervention group
Group type: COMPARATOR
Intervention: Any IV Iron
Number of subjects: 191
Study 30056562 — intervention group
Group type: COMPARATOR
Intervention: Iron Sucrose
Number of subjects: 191
Study 29126461 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred recruitment model
Number of subjects: 171
Study 26451731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport participation
Number of subjects: 414
Study 26451731 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 414
Study 26451731 — intervention group
Group type: EXPERIMENTAL
Intervention: Community social capital
Number of subjects: 414
Study 26451731 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual social capital
Number of subjects: 414
Study 23916928 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (2 g/day), vitamin C (1 g/day), and vitamin E (400 IU/day)
Number of subjects: 203
Study 23916928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 23916928 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids plus vitamins C and E supplementation
Number of subjects: 203
Study 21802920 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg once daily)
Number of subjects: 188
Study 21802920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 19009173 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 202
Study 19009173 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 202
Study 17286569 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP injection during intravenous isoproterenol infusion (ISP-infusion) after successful extensive encircling pulmonary vein isolation (EEPVI)
Number of subjects: 82
Study 17286569 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP injection
Number of subjects: 82
Study 17286569 — intervention group
Group type: COMPARATOR
Intervention: Previous EEPVI without ATP injection
Number of subjects: 82
Study 14556451 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11009237 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.73% lidocaine with ketorolac (4 mg/mL)
Number of subjects: 79
Study 11009237 — intervention group
Group type: COMPARATOR
Intervention: 1.73% lidocaine
Number of subjects: 79
Study 11009237 — intervention group
Group type: COMPARATOR
Intervention: 1.73% lidocaine plus intravenous ketorolac (20 mg)
Number of subjects: 79
Study 11009237 — intervention group
Group type: COMPARATOR
Intervention: 1.73% lidocaine with .67% ethanol
Number of subjects: 79
Study 8883419 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 12
Study 8883419 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 12
Study 1499443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stress (4 degrees C)
Number of subjects: 9
Study 1499443 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus (37 degrees C)
Number of subjects: 9
Study 3974051 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 3974051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31924316 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with docetaxel and prednisone administered every 3 weeks for six cycles
Number of subjects: 298
Study 31924316 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) with observation
Number of subjects: 298
Study 31924316 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with docetaxel and prednisone
Number of subjects: 298
Study 29803638 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE-1034 (3g every 12h)
Number of subjects: 93
Study 29803638 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2g every 12h)
Number of subjects: 93
Study 26241775 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDIC‐treatment (neuromuscular exercise, education, diet, insoles, pain medication)
Number of subjects: 100
Study 26241775 — intervention group
Group type: COMPARATOR
Intervention: Usual care (two leaflets with information and treatment advice)
Number of subjects: 100
Study 24879797 — intervention group
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine (n=495)
Number of subjects: 991
Study 24879797 — intervention group
Group type: COMPARATOR
Intervention: lapatinib plus capecitabine (n=496)
Number of subjects: 991
Study 22434618 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced follow-up
Number of subjects: 42
Study 22434618 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 42
Study 20188239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 16
Study 20188239 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 16
Study 18219836 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI (90 microg; 2 actuations of 45 microg; n = 496)
Number of subjects: 746
Study 18219836 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol HFA MDI (180 microg; 2 actuations of 90 microg; n = 250)
Number of subjects: 746
Study 18219836 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI
Number of subjects: 746
Study 18219836 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol HFA MDI
Number of subjects: 746
Study 16148283 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg daily)
Number of subjects: 760
Study 16148283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 11812271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral/metered-dose inhaler (oral/MDI) regimen
Number of subjects: 34
Study 11812271 — intervention group
Group type: COMPARATOR
Intervention: Intravenous/nebulizer (I.V./neb) regimen
Number of subjects: 34
Study 10351966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use within the 60 minutes preceding the onset of myocardial infarction symptoms
Number of subjects: 3946
Study 10351966 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of cocaine
Number of subjects: 3946
Study 8557001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (0.3 mg kg‐1 ED95)
Number of subjects: 0
Study 8557001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Number of subjects: 0
Study 1834391 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 4.5 micrograms/kg
Number of subjects: 12
Study 1834391 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF 2.0 micrograms/kg
Number of subjects: 12
Study 7094971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (C1) at 75 mg per day
Number of subjects: 31
Study 7094971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (C1) at increasing dosage up to 150 mg per day
Number of subjects: 31
Study 7094971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (C1)
Number of subjects: 31
Study 31833552 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted scars
Number of subjects: 19
Study 31833552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ungrafted scars
Number of subjects: 19
Study 31833552 — intervention group
Group type: COMPARATOR
Intervention: Healthy skin
Number of subjects: 19
Study 31833552 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted flame burn scars
Number of subjects: 19
Study 31833552 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted and ungrafted scars
Number of subjects: 19
Study 30841505 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual plant
Number of subjects: 23
Study 30841505 — intervention group
Group type: COMPARATOR
Intervention: Artificial plant
Number of subjects: 23
Study 30841505 — intervention group
Group type: COMPARATOR
Intervention: Photograph of a plant
Number of subjects: 23
Study 30841505 — intervention group
Group type: COMPARATOR
Intervention: No plant
Number of subjects: 23
Study 28782266 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 185
Study 28782266 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 185
Study 28782266 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 37.5 mg
Number of subjects: 185
Study 28782266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 25298352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (Zingiber officinale) capsules
Number of subjects: 92
Study 25298352 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 92
Study 23963375 — intervention group
Group type: EXPERIMENTAL
Intervention: With tenaculum
Number of subjects: 118
Study 23963375 — intervention group
Group type: COMPARATOR
Intervention: Without tenaculum
Number of subjects: 118
Study 23963375 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 118
Study 23963375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenaculum use
Number of subjects: 118
Study 23963375 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate endometrial sampling
Number of subjects: 118
Study 21450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary cardiovascular risk prediction model
Number of subjects: 7168
Study 21450612 — intervention group
Group type: EXPERIMENTAL
Intervention: External applicability of the model
Number of subjects: 7168
Study 21450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant predictors of cardiovascular events
Number of subjects: 7168
Study 21450612 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiovascular events recorded during follow-up
Number of subjects: 7168
Study 19825326 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (15 mg of sibutramine)
Number of subjects: 62
Study 19825326 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (15 mg of sibutramine)
Number of subjects: 62
Study 17657689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib
Number of subjects: 0
Study 17657689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study 17657689 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic treatment with Verteporfin
Number of subjects: 0
Study 15040533 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a + lamivudine (3TC)
Number of subjects: 63
Study 15040533 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha2b + lamivudine (3TC)
Number of subjects: 63
Study 11438043 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 15 microg/kg once-weekly
Number of subjects: 91
Study 11438043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 9683174 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 3.5x the recommended dietary intake (RDI) of folate and vitamin B12 in wheat bran cereal for three months followed by ten times the RDI via tablets for a further three months
Number of subjects: 106
Study 9683174 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 3.5x the recommended dietary intake (RDI) of folate and vitamin B12
Number of subjects: 106
Study 9683174 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 106
Study 7881228 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based homes (movers)
Number of subjects: 36
Study 7881228 — intervention group
Group type: COMPARATOR
Intervention: Hospital (non-movers)
Number of subjects: 36
Study 2452491 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) during hospital stay
Number of subjects: 23
Study 2452491 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous oral intake only during hospital stay
Number of subjects: 23
Study 29361959 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition (PN) strategy
Number of subjects: 100
Study 29361959 — intervention group
Group type: COMPARATOR
Intervention: Usual care enteral nutrition (EN) delivery
Number of subjects: 100
Study 29361959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 27612653 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus reuteri
Number of subjects: 290
Study 27612653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 25644724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caffeine (loading 40 mg/kg/day and maintenance 20 mg/kg/day)
Number of subjects: 120
Study 23659814 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapeutic conversation intervention (FAM-TC)
Number of subjects: 0
Study 21128833 — intervention group
Group type: EXPERIMENTAL
Intervention: Anomia therapy involving cueing to improve retrieval of nouns, specific dosage and duration not mentioned.
Number of subjects: 13
Study 21128833 — intervention group
Group type: EXPERIMENTAL
Intervention: Anomia therapy (same as above)
Number of subjects: 13
Study 18498792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap left intact distally (D group)
Number of subjects: 160
Study 18498792 — intervention group
Group type: COMPARATOR
Intervention: Intercostal muscle flap cut distally (C group)
Number of subjects: 160
Study 16536959 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 225
Study 16536959 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study 12681025 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 0
Study 12681025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (t.i.d.)
Number of subjects: 0
Study 11165725 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary monitoring (n=69)
Number of subjects: 130
Study 11165725 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital monitoring (n=61)
Number of subjects: 130
Study 11165725 — intervention group
Group type: COMPARATOR
Intervention: Low-risk pregnant women (n=55)
Number of subjects: 130
Study 9484423 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily
Number of subjects: 0
Study 9484423 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg daily
Number of subjects: 0
Study 9484423 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg and 400 mg daily
Number of subjects: 0
Study 9484423 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 9484423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8159602 — intervention group
Group type: EXPERIMENTAL
Intervention: Picenadol 30 mg
Number of subjects: 408
Study 8159602 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 90 mg
Number of subjects: 408
Study 8159602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 2831758 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg captopril (group C; n = 12)
Number of subjects: 24
Study 2831758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P; n = 12)
Number of subjects: 24
Study 31305506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice packs
Number of subjects: 42
Study 31305506 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature pack
Number of subjects: 42
Study 31486727 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Palliative Care (HBPC)
Number of subjects: 1155
Study 31486727 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual primary care
Number of subjects: 1155
Study 31486727 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-reported outcome measures
Number of subjects: 1155
Study 31486727 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver outcome measures
Number of subjects: 1155
Study 31486727 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant survival time
Number of subjects: 1155
Study 31486727 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' emergency department visits and hospitalizations
Number of subjects: 1155